Saigo K.,Himeji Dokkyo University |
Takenokuchi M.,Himeji Dokkyo University |
Hiramatsu Y.,Red Cross |
Tada H.,Red Cross |
And 5 more authors.
Journal of International Medical Research | Year: 2011
Reactive oxygen species (ROS) and serum ferritin levels are both considered to be important biological factors in the pathogenesis of myelodysplastic syndrome (MDS). This study evaluated the levels of ROS in 40 patients with MDS (19 males and 21 females) using the Free Radical Analytical System, FRAS4, and derivatives of reactive oxygen metabolite kits. The patients' mean age was 67.3 years (range 58 - 86 years). The sera of 34 (85%) patients exhibited higher levels of oxidative stress than the reference range. There was a positive correlation between ROS levels and serum ferritin levels, and a negative correlation between ROS levels and haemoglobin levels. There was a negative relationship between serum haemoglobin and ferritin levels. The results indicated that iron accumulation or severe anaemia could contribute to oxidative stress in MDS patients. Iron chelation and antioxidant therapy may be suitable for the management of MDS. © 2011 Field House Publishing LLP.
Nakashima K.,Akoh Central Hospital |
Nakashima K.,Kawasaki Medical School |
Tanabe A.,Akoh Central Hospital |
Tanabe A.,Kawasaki Medical School |
And 11 more authors.
Journal of the Japan Diabetes Society | Year: 2013
We investigated the early effects of short-term intensive insulin therapy (STIIT) in 174 type 2 diabetic patients with Hb Alc level 8.4 % and above. We also compared the long-term effects of voglibose and metformin after STIIT in 74 newly diagnosed patients and 64 previously treated patients. STIIT significantly decreased the levels of blood glucose and high-sensitivity C-reactive protein and the HOMA-IR scores and increased the HOMA-β scores. The HbAlc levels were correlated with the blood glucose levels and inversely correlated with the HOMA-β scores and duration of diabetes before STIIT; however, three months after treatment, the HbAlc levels were directly correlated with the duration of diabetes, reflecting the basic β-cell function under the subsidence of glucose toxicity. The newly diagnosed patients exhibited significantly stronger improvements than the previously treated patients (HbAlc level less than 6.9 %: 66 % vs. 30 %). The patients with a shorter duration of diabetes demonstrated better responses to STIIT than those with a longer duration of diabetes. A multiple logistic regression analysis adjusted for age and gender showed that both factors independently contributed to the improvements. Among the previously treated patients, some patients exhibited difficulties during treatment, while others demonstrated β-cell preservation. Early relief from glucose toxicity due to STIIT offers substantial benefits to patients with poorly controlled type 2 diabetes.